NCT05387837: An overdue trial by Ashvattha Therapeutics, Inc.
This trial is overdue. It was due to report 1 month, 1 week ago.
Think we've made a mistake? Before contacting us, review the criteria in our paper. In particular, bear in mind the following:
- We can only rely on the structured data that sponsors put into the registry: they may enter incorrect or incomplete data.
- Reporting in a journal is not enough. The FDAAA rules state that the trial must be reported on ClinicalTrials.gov.
- Terminated trials are required to report results. Only withdrawn trials (which never recruited a single patient) are not.
Full data
| Full entry on ClinicalTrials.gov | NCT05387837 |
|---|---|
| Title | A 3 Stage Ph 2 Study: St 1: Single SubQ D-4517.2 Dose Safety and PD in Wet wAMD or DME. Stage 1A: Multiple SubQ D-4517.2 Dose Safety, PK and PD in wAMD and DME. Stage 2: Safety, Tolerability, PK and Efficacy of SubQ D-4517.2 in wAMD |
| Results Status | Overdue |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 31, 2022 |
| Completion date | May 9, 2025 |
| Required reporting date | May 9, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | June 19, 2026 |
| Days late | 41 |